Adaptimmune Therapeutics PLC SEC filings ADAPY
Adaptimmune Therapeutics PLC has 808 filings in SEC EDGAR's recent list, going back to Oct 2, 2014. Its latest annual report, Form ARS, was filed on Apr 25, 2025 for the period ended Dec 31, 2024. The latest quarterly report (Form 10-Q) was filed on Aug 13, 2025, covering the quarter ended Jun 30, 2025. The most recent current report (Form 8-K) was filed on Oct 20, 2025 (listing notice, regulation fd disclosure). The company's fiscal year ends on December 31.
| Form | Description | Filed | Period |
|---|---|---|---|
| DEF 14A | Proxy statement | Apr 25, 2025 | May 29, 2025 |
| PRE 14A | Preliminary proxy statement | Apr 15, 2025 | May 29, 2025 |
| DEF 14A | Proxy statement | Apr 11, 2024 | May 14, 2024 |
| PRE 14A | Preliminary proxy statement | Apr 1, 2024 | May 14, 2024 |
| DEF 14A | Proxy statement | Apr 13, 2023 | — |
| PRE 14A | Preliminary proxy statement | Apr 3, 2023 | — |
| DEF 14A | Proxy statement | Apr 21, 2022 | May 25, 2022 |
| PRE 14A | Preliminary proxy statement | Apr 11, 2022 | May 25, 2022 |
| DEF 14A | Proxy statement | Apr 8, 2021 | May 14, 2021 |
| PRE 14A | Preliminary proxy statement | Mar 29, 2021 | May 14, 2021 |
| DEF 14A | Proxy statement | Apr 20, 2020 | May 29, 2020 |
| PRE 14A | Preliminary proxy statement | Apr 8, 2020 | May 29, 2020 |
| DEF 14A | Proxy statement | Mar 15, 2019 | May 2, 2019 |
| PRE 14A | Preliminary proxy statement | Mar 1, 2019 | Mar 1, 2019 |
| DEF 14A | Proxy statement | Apr 27, 2018 | Jun 20, 2018 |
| DEF 14A | Proxy statement | Apr 28, 2017 | Jun 21, 2017 |
| PRE 14A | Preliminary proxy statement | Apr 12, 2017 | Jun 21, 2017 |
Showing 17 filings. Main filings leave out insider and ownership forms such as Form 4; choose a type above to see them. Each form opens on SEC.gov. Older filings are on SEC EDGAR.
New to this? Read What Are SEC Filings? 10-K, 10-Q, 8-K and Other Forms Explained.
Company profile
- Industry
- Biological Products, (No Diagnostic Substances) (SIC 2836)
- Listed as
- ADAPY (OTC)
- Fiscal year ends
- December 31
- Incorporated in
- United Kingdom
- Headquarters
- Abingdon, Oxfordshire
- SEC filer status
- Non-accelerated filer, Smaller reporting company
- SEC CIK
- 1621227
- Former names
- Adaptimmune Ltd (until Mar 17, 2015)
Other Biological Products, (No Diagnostic Substances) companies
- Amgen Inc AMGN
- Gilead Sciences, Inc. GILD
- Moderna, Inc. MRNA
- Argenx SE ARGX
- Revolution Medicines, Inc. RVMD
- Biogen Inc. BIIB
- BioNTech SE BNTX
- Exelixis, Inc. EXEL
All 182 Biological Products, (No Diagnostic Substances) companies
Source: SEC EDGAR filings. This is company-reported data, not investment advice.